Nektar Therapeutics
NKTR36.810USD
+1.690+4.81%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
723.41MCap. mercado
PérdidaP/E TTM
Más Datos de Nektar Therapeutics Compañía
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Información de Nektar Therapeutics
Símbolo de cotizaciónNKTR
Nombre de la empresaNektar Therapeutics
Fecha de salida a bolsaMay 03, 1994
Director ejecutivoRobin (Howard W)
Número de empleados61
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 03
Dirección455 Mission Bay Boulevard South
CiudadSAN FRANCISCO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94158
Teléfono18554826587
Sitio Webhttps://www.nektar.com/
Símbolo de cotizaciónNKTR
Fecha de salida a bolsaMay 03, 1994
Director ejecutivoRobin (Howard W)
Ejecutivos de Nektar Therapeutics
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Howard W. Robin
Mr. Howard W. Robin
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
68.40K
+21667.00%
Dr. Jonathan Zalevsky, Ph.D.
Dr. Jonathan Zalevsky, Ph.D.
Senior Vice President, Chief Research and Development Officer
Senior Vice President, Chief Research and Development Officer
19.04K
-3867.00%
Mr. Jeffrey Robert (Jeff) Ajer
Mr. Jeffrey Robert (Jeff) Ajer
Independent Director
Independent Director
2.28K
--
Mr. Robert B. (Rob) Chess
Mr. Robert B. (Rob) Chess
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Roy A. Whitfield
Mr. Roy A. Whitfield
Lead Independent Director
Lead Independent Director
--
--
Mr. R. Scott Greer
Mr. R. Scott Greer
Independent Director
Independent Director
--
--
Mr. Mark A. Wilson, J.D.
Mr. Mark A. Wilson, J.D.
Senior Vice President, Chief Legal Officer
Senior Vice President, Chief Legal Officer
--
--
Dr. Diana M. Brainard, M.D.
Dr. Diana M. Brainard, M.D.
Independent Director
Independent Director
--
--
Ms. Sandra A. Gardiner
Ms. Sandra A. Gardiner
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Mr. Corey Davis
Mr. Corey Davis
Managing Director
Managing Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Howard W. Robin
Mr. Howard W. Robin
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
68.40K
+21667.00%
Dr. Jonathan Zalevsky, Ph.D.
Dr. Jonathan Zalevsky, Ph.D.
Senior Vice President, Chief Research and Development Officer
Senior Vice President, Chief Research and Development Officer
19.04K
-3867.00%
Mr. Jeffrey Robert (Jeff) Ajer
Mr. Jeffrey Robert (Jeff) Ajer
Independent Director
Independent Director
2.28K
--
Mr. Robert B. (Rob) Chess
Mr. Robert B. (Rob) Chess
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Roy A. Whitfield
Mr. Roy A. Whitfield
Lead Independent Director
Lead Independent Director
--
--
Mr. R. Scott Greer
Mr. R. Scott Greer
Independent Director
Independent Director
--
--
Desglose de ingresos
Divisa: USDActualizado: mar., 6 de ene
Divisa: USDActualizado: mar., 6 de ene
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
La empresa aún no ha revelado los datos relevantes.
Por regiónUSD
Nombre
Ganancia
Proporción
Rest of world
97.05M
98.60%
United States
1.38M
1.40%
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: sáb., 7 de feb
Actualizado: sáb., 7 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BVF Partners L.P.
6.28%
The Vanguard Group, Inc.
5.03%
Susquehanna International Group, LLP
4.55%
Morgan Stanley & Co. LLC
4.34%
Farallon Capital Management, L.L.C.
3.89%
Otro
75.92%
Accionistas
Accionistas
Proporción
BVF Partners L.P.
6.28%
The Vanguard Group, Inc.
5.03%
Susquehanna International Group, LLP
4.55%
Morgan Stanley & Co. LLC
4.34%
Farallon Capital Management, L.L.C.
3.89%
Otro
75.92%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
31.98%
Investment Advisor
23.75%
Investment Advisor/Hedge Fund
8.82%
Research Firm
7.03%
Individual Investor
0.82%
Pension Fund
0.76%
Venture Capital
0.75%
Sovereign Wealth Fund
0.25%
Otro
25.84%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
373
14.85M
73.02%
+2.42M
2025Q3
342
9.79M
51.46%
-2.29M
2025Q2
342
8.92M
53.56%
-2.95M
2025Q1
408
8.48M
68.15%
-4.47M
2024Q4
427
136.20M
73.84%
-69.28M
2024Q3
442
143.71M
78.07%
-57.20M
2024Q2
458
138.43M
75.38%
-54.08M
2024Q1
477
115.32M
62.79%
-91.21M
2023Q4
499
122.94M
64.45%
-94.24M
2023Q3
522
148.15M
77.94%
-68.45M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BVF Partners L.P.
1.28M
6.28%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
948.65K
4.66%
+219.16K
+30.04%
Sep 30, 2025
Susquehanna International Group, LLP
924.90K
4.55%
+703.00K
+316.82%
Sep 30, 2025
Morgan Stanley & Co. LLC
883.58K
4.34%
+822.95K
+1357.26%
Sep 30, 2025
Farallon Capital Management, L.L.C.
791.00K
3.89%
+791.00K
--
Sep 30, 2025
Two Sigma Investments, LP
613.14K
3.01%
+533.75K
+672.27%
Sep 30, 2025
Emerald Advisers LLC
556.45K
2.74%
+382.56K
+220.00%
Sep 30, 2025
Millennium Management LLC
545.99K
2.68%
-103.04K
-15.88%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
476.31K
2.34%
+178.50K
+59.94%
Sep 30, 2025
Nantahala Capital Management, LLC
418.52K
2.06%
-291.24K
-41.03%
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Invesco Dorsey Wright Healthcare Momentum ETF
4.55%
Simplify Health Care ETF
3.22%
Simplify Propel Opportunities ETF
2.69%
State Street SPDR S&P Pharmaceuticals ETF
1.72%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.48%
Invesco NASDAQ Future Gen 200 ETF
1.17%
Invesco Dorsey Wright SmallCap Momentum ETF
0.95%
iShares U.S. Pharmaceuticals ETF
0.46%
Invesco RAFI US 1500 Small-Mid ETF
0.13%
Schwab U.S. Small-Cap ETF
0.03%
Ver más
Invesco Dorsey Wright Healthcare Momentum ETF
Proporción4.55%
Simplify Health Care ETF
Proporción3.22%
Simplify Propel Opportunities ETF
Proporción2.69%
State Street SPDR S&P Pharmaceuticals ETF
Proporción1.72%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporción1.48%
Invesco NASDAQ Future Gen 200 ETF
Proporción1.17%
Invesco Dorsey Wright SmallCap Momentum ETF
Proporción0.95%
iShares U.S. Pharmaceuticals ETF
Proporción0.46%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0.13%
Schwab U.S. Small-Cap ETF
Proporción0.03%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Jun 04, 2025
Merger
15→1
Fecha
Fecha ex-dividendo
Tipo
Relación
Jun 04, 2025
Merger
15→1
